# Vivani Medical (VANI) — News

VANI · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/vani/news

## Recent headlines

- [Vunani - Expects headline EPS of 14.4-16.3 cents for six months ended Aug 31, 2026](https://www.ainvest.com/news/vunani-expects-headline-eps-14-4-16-3-cents-months-ended-aug-31-2026-2610) — AInvest Wire, Oct 14, 2026
  Vunani Ltd. (JSE:VUN) has provided an earnings forecast for the six months ended August 31, 2026, expecting headline earnings per share (EPS) to range between 14.4 and 16.3 cents. This guidance reflects the company’s performance outlook amid ongoing operational and strategic initiatives. While no…
- [Vivani Medical reports second quarter 2026 financial results and provides business update](https://www.ainvest.com/news/vivani-medical-reports-quarter-2026-financial-results-business-update-2608) — AInvest Wire, Aug 13, 2026
- **Important** — [Vivani Medical, Inc.: Vivani Medical menandatangani perjanjian dengan Novo Nordisk bagi menilai NPM-139, implan semaglutide](https://www.ainvest.com/news/vivani-medical-vivani-medical-menandatangani-perjanjian-dengan-novo-nordisk-bagi-menilai-npm-139-implan-semaglutide-2607) — AInvest Wire, Jul 8, 2026
- [Vivani Medical: No exclusivity provisions for NPM-139, or Vivani's proprietary nanoportal technology associated with agreement with Novo Nordisk](https://www.ainvest.com/news/vivani-medical-exclusivity-provisions-npm-139-vivani-proprietary-nanoportal-technology-agreement-novo-nordisk-2607) — AInvest Wire, Jul 7, 2026
  Vivani Medical, Inc. and Novo Nordisk have entered into an agreement to evaluate NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management, with no exclusivity provisions applied to NPM-139 or Vivani’s proprietary nanoportal technology under the arrangement,…
- [Vivani Medical, Inc.: Vivani Medical in pact with Novo Nordisk to evaluate NPM-139, a miniature, ultra long-acting semaglutide](https://www.ainvest.com/news/vivani-medical-vivani-medical-pact-novo-nordisk-evaluate-npm-139-miniature-ultra-long-acting-semaglutide-2607) — AInvest Wire, Jul 7, 2026
  Vivani Medical, Inc. (NASDAQ: VANI) has announced a collaboration with Novo Nordisk A/S, the developer of Ozempic® and Wegovy®, to evaluate miniature ultra long-acting semaglutide implant . This partnership follows promising preclinical and early clinical data demonstrating the potential of NPM-139…

## Similar Stocks

- [COCH](https://www.lighthorse.io/tickers/coch) — Envoy Medical, Inc. - Class A Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).